The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of Warfarin: Assessment of a Standardized Periprocedural Anticoagulation Regimen
Abstract
BACKGROUND: The treatment of patients at increased risk for arterial thromboembolism who require temporary interruption of warfarin sodium therapy is a common clinical problem. We investigated the efficacy and safety of a standardized periprocedural anticoagulation regimen with low-molecular-weight heparin. METHODS: We studied 650 consecutive patients with a mechanical heart valve, chronic atrial fibrillation, or embolic stroke who required interruption of warfarin therapy because of an invasive procedure. Warfarin was stopped 5 or 6 days before the procedure, and patients received subcutaneous dalteparin sodium, 100 IU/kg twice daily, starting 3 days before the procedure. The risk of postprocedural bleeding determined postprocedural anticoagulant management. In patients undergoing a non-high-bleeding-risk procedure who had adequate postprocedural hemostasis, warfarin was resumed on the evening of the procedure, and dalteparin sodium, 100 IU/kg twice daily, was resumed on the next day and continued until the international normalized ratio was 2.0 or more. If postprocedural hemostasis was not secured, the resumption of dalteparin was delayed. In patients undergoing a high-bleeding-risk procedure, warfarin was resumed on the evening of the procedure, but dalteparin was not given after the procedure. RESULTS: Patients were followed up during the preprocedural and postprocedural period for a mean of 13.8 days (range, 10-18 days). In 542 patients who underwent a non-high-bleeding-risk procedure, there were 2 thromboembolic events (0.4%), 4 major bleeding episodes (0.7%), and 32 episodes of increased wound-related blood loss that precluded postprocedural dalteparin administration (5.9%). In 108 patients who underwent a high-bleeding-risk procedure, there were 2 deaths (1.8%) possibly due to thromboembolism and 2 major bleeding episodes (1.8%). CONCLUSIONS: In patients at increased risk for arterial thromboembolism who require temporary interruption of warfarin therapy, a standardized periprocedural anticoagulant regimen with low-molecular-weight heparin is associated with a low risk of thromboembolic and major bleeding complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldhaber, S. Z., Visani, L., & De Rosa, M. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07534-5 · Cited by 2,870
Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (2001) · Chest · doi:10.1378/chest.119.1_suppl.64s · Cited by 1,580
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Landefeld, S., & Kearon, C. (2001) · Chest · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,134
ACC/AHA guidelines for the management of patients with valvular heart disease
Bonow, R., Carabello, B., de Leon, A., Edmunds, L. H., Fedderly, B., Freed, M., Gaasch, W., McKay, C., Nishimura, R., O’Gara, P., et al. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00454-9 · Cited by 1,134
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02110-3 · Cited by 1,076
Kasper, W., Konstantinides, S., Geibel, A., Olschewski, M., Heinrich, F., Grosser, K. D., Rauber, K., Iversen, S., Redecker, M., & Kienast, J. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00319-7 · Cited by 1,034
Horlocker, T. (2003) · Regional Anesthesia and Pain Medicine · doi:10.1053/rapm.2003.50046 · Cited by 921
Management of Anticoagulation before and after Elective Surgery
Kearon, C., & Hirsh, J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705223362107 · Cited by 812
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
Self-citationAspirin and Mortality from Coronary Bypass Surgery
Mangano, D. T. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020798 · Cited by 674
Cited by
Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., Dunn, A. S., & Kunz, R. (2012) · Chest · doi:10.1378/chest.11-2298 · Cited by 1,641
Self-citationACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E. L., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.003 · Cited by 1,428
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
Douketis, J. D., Spyropoulos, A. C., Kaatz, S., Becker, R. C., Caprini, J. A., Dunn, A. S., Garcia, D. A., Jacobson, A., Jaffer, A. K., Kong, D. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501035 · Cited by 1,184
The Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., & Ansell, J. (2008) · Chest · doi:10.1378/chest.08-0675 · Cited by 830
Self-citationAuthors/Task Force Members, Poldermans, D., Bax, J. J., Boersma, E., De Hert, S., Eeckhout, E., Fowkes, G., Gorenek, B., Hennerici, M. G., Iung, B., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp337 · Cited by 738
Metadata
- Authors
- Douketis, J. D., Johnson, J. A., & Turpie, A. G.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2004-06-28
- Volume
- 164
- Issue
- 12
- Pages
- 1319
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2134541635
- Cited by
- 328
- References
- 32
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of Warfarin: Assessment of a Standardized Periprocedural Anticoagulation Regimen. https://app.cochat.ai/papers/10.1001/archinte.164.12.1319
- The paper
- Douketis, J. D., Johnson, J. A., & Turpie, A. G. (2004). Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of Warfarin: Assessment of a Standardized Periprocedural Anticoagulation Regimen. Archives of Internal Medicine. https://doi.org/10.1001/archinte.164.12.1319
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.